DAHLIANCT06678659
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
At risk: Primary completion moved at least 8 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Oct 30, 2028 to Jul 2029 Show 5 more changesShow less
- Enrollment increased: 170 → 310 participants
- Eligibility criteria expanded, about 6 words
- Trial arms changed: 9 → 11
- Study sites: 7 to 8
- Study description shortened, about 11 words
- Minor Study sites: 6 to 7v10
Notable Enrollment target: 85 to 170v9 Show 5 more changesShow less
- Eligibility criteria expanded, about 10 words
- Primary endpoints revised (3)
- Study description shortened, about 24 words
- Site details revised at 3 of 6 sites
- Study arms: 4 to 9
- Minor Site details revised at 4 of 6 sitesv8
Notable Eligibility criteria expanded, about 14 wordsv7 Show 5 more changesShow less
- Primary endpoints revised (3)
- Study sites: 5 to 6
- Secondary endpoints: 10 to 11
- Study description revised
- Study arms: 3 to 4
Show 5 earlier versionsHide 5 earlier versions
- Minor Study sites: 4 to 5v6
- Minor Site contacts updated at 4 of 4 sitesv5
- Minor Study sites: 3 to 4v4
- Minor Study sites: 1 to 3v3
- Minor Start date: Nov 5, 2024 to Nov 21, 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Phase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs)
Timeframe: Initiation of study drug through 4 weeks
Phase 1 and 2 - Number of Participants With a Treatment-emergent Adverse Event
Timeframe: Initiation of study drug through 30 days after the last dose (up to approximately 24 months)
Phase 2- Objective Response Rate (ORR)
Timeframe: Initiation from study drug until disease progression (up to approximately 24 months)
Secondary (11)
Phase 1- ORR
Phase 1 and 2- Disease Control Rate (DCR)
Phase 1 and 2 - Duration of Response (DOR)
Phase 1 and 2 - Duration of Stable Disease (SD)
Phase 1 and 2 - Time to Response (TTR)
Show 6 moreShow less
Phase 1 and 2 - Progression Free Survival (PFS)
Phase 1 and 2 - Overall Survival (OS)
Phase 1 - Maximum Plasma Concentration (Cmax)
Phase 1 - Time to Reach Maximum Plasma Concentration (Tmax)
Phase 1 - Plasma Concentration Before the Next Dose (Ctrough)
Phase 1 - Area Under Plasma Concentration-time Curve (AUC)
Arms and interventions
Phase 1aExperimental
Dose Finding
Phase 1b Cohort AExperimental
Phase 1b Cohort BExperimental
Phase 1b Cohort CExperimental
Phase 1b Cohort DExperimental
Phase 1b Cohort EExperimental
Phase 1b Cohort FExperimental
Phase 2 Cohort 1 Dose #1Experimental
Phase 2 Cohort 1 Dose #2Experimental
Phase 2 Cohort 2 Dose #1Experimental
Phase 2 Cohort 2 Dose #2Experimental
Drugs: REC-1245
Sites
8 sites in 2 countries
United States 6, Canada 2